Shares in HemoGenyx Pharmaceuticals Plc (LSE: HEMO), the London Main Market-listed clinical-stage biotech, climbed about 6.71% to 604.00p in the early-November 2026 session on thin Volume (LSE:HEMO). With a Market Value near £39.04 million and no earnings, the move raises a clear question for biotech watchers: is clinical progress in the group's cell-therapy programme beginning to win over investors?

Latest Developments

HemoGenyx has been advancing its Phase I trial of HG-CT-1, a CAR-T cell therapy for relapsed or refractory acute myeloid leukaemia (AML). (LSE:HEMO) Company announcements during 2026 reported the treatment of a third patient and continued recruitment, with the group opening its first clinical site for the leukaemia-therapy trial. It has also raised funds to support the clinical programme, including a prospectus and fundraising activity in late 2025, and reported successful process-qualification runs for the manufacture of its therapy. AML is an aggressive blood cancer with poor outcomes in the relapsed or refractory setting, so a novel CAR-T approach, if it proves safe and effective, could address a significant unmet need.

What the Numbers Show

The early-November 2026 shows HEMO at 604.00p, up 6.71% on light volume of about 12,300 shares. (LSE:HEMO) Market Capitalisation stands near £39.04 million, with a low Beta of 0.73. The company is loss-making, with Earnings per share of about -£1.80, no price-to-earnings ratio and no dividend, giving a Yield of 0%. The 's earnings-change reading is +18.57%, consistent with a narrowing of losses on a per-share basis.

Why Investors Are Watching

HemoGenyx carries no formal third-party data-provider rating, typical of small clinical-stage biotechs. Investor attention centres on the AML programme, an area of high unmet medical need, and on the group's broader CAR-T and bispecific antibody pipeline. Clinical-trial milestones — patient dosing, safety read-outs and recruitment progress — are the principal drivers of sentiment, and the low trading volume means each can produce outsized price moves.

What Could Come Next

The next catalysts are likely to be further safety and early efficacy data from the HG-CT-1 trial, additional patient cohorts and any regulatory interactions. Progress on partnering or licensing, and updates on the group's wider pipeline — which includes bispecific antibody candidates alongside the lead CAR-T programme — could also move the shares. As a development-stage company with no product revenue, HemoGenyx will need continued access to funding to complete its trials, so the terms and timing of any future capital raises will be watched closely.

Risks to Watch

Clinical-stage biotech is inherently high risk: trials can fail, safety issues can emerge and timelines can slip. HemoGenyx is loss-making and will likely require further fundraising, which could dilute existing shareholders. The very low trading volume makes the shares Illiquid and prone to sharp swings on modest order flow. Competition in the CAR-T and blood-cancer space is intense, with far larger, better-funded rivals, and any adverse safety signal could set the programme back materially. With no revenue, no Dividend and no rating, the Investment case rests entirely on clinical and regulatory outcomes.

Conclusion

HemoGenyx's roughly 6.71% rise to 604.00p in the early-November 2026 session reflects investor focus on its AML cell-therapy trial, even on very light volume. The group has reported steady clinical progress through 2026, but it remains an early-stage, loss-making biotech dependent on future data and funding. Upcoming trial read-outs will be decisive for the shares.